SLC5A2 and heart failure: There is unequivocal evidence that sacubitril/valsartan, a beta‐blocker, an MRA and an SGLT2 inhibitor are the “foundational” therapies that should, where possible, be prescribed to all patients with HFrEF to maximize their survival and minimize their risk of worsening heart failure, leading to deterioration in symptoms and quality of life and admission to hospital.